Datapoint: AbbVie Scores Ulcerative Colitis Nod for Rinvoq

The FDA last week approved AbbVie’s Rinvoq for the treatment of ulcerative colitis, the JAK inhibitor’s third label expansion in the past four months. Rinvoq was first approved in rheumatoid arthritis in 2019. For the treatment of the disease, the JAK inhibitor holds covered or better status for 96% of all insured lives. 36% of all covered lives have preferred access to Rinvoq, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/23/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 2

Datapoint: Blue Shield of California Launches Virtual-First Plan

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 1

Datapoint: FDA Approves Lilly’s Jaypirca in Blood Cancer

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 31

Datapoint: Independence Blue Cross to Launch Advanced Network for Gene Therapies

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today